WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the following conferences:
